National Cancer Institute · company speakers →
Dr. Mehdi Benzaoui will discuss the impact of manufacturing, and specifically the potential for the T cell stimulation method to modulate the phenotype and function of chimeric antigen receptor T cells. While clinical trials using CD19 and CD22 CAR T-cells to treat patients with acute lymphocytic leukemia and B-lineage lymphomas have been impressively successful, it is of interest to note that these trials have differed in the methods used to generate the CAR T cells––as a function of the T cell selection method, media, cytokines, TCR activation protocol, and timing, amongst others. Here, Dr. Benzaoui will present data showing that CD19 CAR T-cells generated using a soluble, tunable activation platform based on DNA hybridization.
Is this you? Claim this profile →
No public contact links on file.
Sourcing speakers for your event?
Browse the speaker directory →